Efficacy and Safety of IVIG-L in ITP Patients

Prothya Biosolutions

Status and phase

Completed

Phase 3

Conditions

Purpura, Thrombocytopenic, Idiopathic

Treatments

Drug: IVIG-L

Study type

Interventional

Funder types

Industry

Identifiers

NCT00151840

KB98001

Details and patient eligibility

About

The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.

Full description

Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of intravenous immunoglobulin simplifies infusion, eliminates possible mistakes in the reconstitution with water for injection and reduces space requirements in storage.

In addition to donor selection and screening, several procedures have been included in the production process to improve viral safety.

In this clinical trial, the efficacy and safety of IVIG-L in patients with ITP will be assessed and compared with data obtained from literature. IVIG-L will also be studied in patients with hypogammaglobulinemia.The results from both studies will be used for an application for marketing authorisation of IVIG-L in Finland and the Netherlands.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with chronic ITP with a platelet count of about 20x109/L and at high risk of bleeding
Patients with chronic ITP with a platelet count of about 20x109/L, who have to undergo surgery
A stable clinical situation (no activity of any other disease)
Age at least 18 yrs
The patient/legally acceptable representative has signed the consent form

Exclusion criteria

The presence of another autoimmune disease related with thrombocytopenia such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) or nephritis
Patients with drug-induced thrombocytopenia or immunologic thrombocytopenia of infectious origin (in particular, Hepatitis, Epstein-Barr virus, Toxoplasma, HIV)
Massive splenomegaly
Treatment with any other investigational drug within 7 days before study entry or previous enrolment in this study
Having an ongoing progressive terminal disease, including HIV infection
Known with allergic reactions against human plasma, plasma products or intravenous immunoglobulin
Presence of conditions predisposing for bleeding: anaemia (hemoglobin < 5.5 mmol/L), renal or urogenital disease, malignant disease (with the exception of basalioma, cervix carcinoma in situ), history of intracranial or aortic aneurysm, stroke, oeso-gastro-intestinal disorders with a bleeding potential, severe hypertension (diastole > 110 mm Hg).
Use of corticosteroids for an acute situation within 7 days before study entry. Patients using corticosteroids prophylactically can be included
Splenectomy in the previous two weeks
Renal insufficiency (plasma creatinine > 115µmol/L)
Pregnancy or lactation
Known with insufficiency of coronary or cerebral circulation
IgA deficiency and anti-IgA antibodies